Novavax Inc

NVAX remains in a Stage 4 decline with active lower highs & lower lows and a medium-term bearish bias. Price is trading below declining EMAs in an extreme oversold context, making immediate selling unfavorable. Execution favors deferring sell orders until rallies into EMA resistance zones provide cleaner entry points.

• ↑Sanofi partnership triggers $175M milestone payment and ongoing royalties.
• ↑Pipeline diversifies into C. diff and oncology programs by 2027.
• ↓Total revenue fell 79% YoY to $140M, signaling sharp decline.